Worldwide stem cell therapy market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330 million by 2020. The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market.
In 2015, North America will hold the largest share of the global stem cell therapy market. This large share is primarily attributed to the extensive government funding and increasing fast-track approval for stem cell therapeutics by the FDA. Moreover, development of advanced genomic methods for stem cell analysis and high number of ongoing research activities are further fueling the growth of the stem cell therapy market in North America. However, the Asia-Pacific stem cell therapy market is expected to grow at the highest CAGR in the forecast period, owing to factors such as increasing regulatory support through favorable government policies, strong product pipelines, and increasing licensing activities in this region.
Companies profiled in this stem cell therapy industry research report include Aastrom Biosciences Inc., Advanced Cell Technologies, Inc., Athersys Inc., Celgene Corporation, Cellular Dynamics International, Cytori Therapeutics, Inc., Fibrocell Science, Inc., Gamida Cell Ltd., Mesoblast Ltd., Pluristem Therapeutics Inc. and Stemcells Inc.
In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012.
Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth.
Geographically, North America is forecasted to command the largest share of the global stem cell therapy market in 2015, followed by Asia-Pacific. A number of factors such as extensive government funding and increasing grant of orphan drug status for stem cell therapeutics by FDA, and presence of major leading companies are driving the growth of the stem cell therapy market in North America. However, the economic slowdown and unfavorable reimbursement scenario for the stem cell therapy constraints the growth of the market in this region. The Asia-Pacific region is poised to grow at the highest CAGR in the next five years. Factors such as huge patient population base, increasing regulatory support through favorable government policies, strong product pipeline of stem cell therapies, and rising licensing activities are propelling the growth of the stem cell therapy market in the Asia-Pacific region.
From an insight perspective, this research report focuses on various levels of analysis-industry analysis (pipeline analysis and investor’s network), regulatory scenario, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high growth segments of the stem cell therapy market, high-growth regions and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities. The above mentioned market research data, current market size, and forecast of future trends will help existing players and new entrants to make the necessary decisions regarding the product offerings, geographic focus, change in strategic approach, R&D investments for innovation in products and technologies, and levels of output in order to remain successful.
Companies purchasing the report could use any one or combination of the below mentioned five strategies for reaping the market share.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on stem cell therapy pipeline product portfolio offered by the top players in the stem cell therapy market. The report analyzes the products market by category/end user across geographies.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals in the stem cell therapy market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various stem cell therapy products across geographies.
- Market Diversification: Exhaustive information about pipeline products, targeted disease area, untapped geographies, recent developments, and investments in the stem cell therapy market.
- Competitive Assessment: In-depth assessment of market shares for pipeline products, strategies, targeted disease area, distribution networks, and manufacturing capabilities of leading players in the stem cell therapy market.